TNFRSF17 and plasma cell myeloma: B-cell maturation antigen (BCMA) of multiple myeloma is one of most studied tumor antigens among CAR T therapy, which showed promising efficacy and clinical manageable side effects in different clinical trials on multiple myeloma (97–99).